Influence of an allogenic collagen scaffold on implant sites with thin supracrestal tissue height: a randomized clinical trial.

Abstract

This randomized clinical trial focused on patients with thin peri-implant soft-tissue height (STH) (≤ 2.5mm) and investigated the impact of an allogenic collagen scaffold (aCS) on supracrestal tissue height and marginal bone loss (MBL). Forty patients received bone level implants and were randomly assigned to the test group with simultaneous tissue thickening with aCS or the control group. After three months, prosthetic restoration occurred. STH measurements were taken at baseline (T0) and reopening surgery (TR), with MBL assessed at 12 months (T1). Descriptive statistics were calculated for continuous variables, and counts for categorical variables (significance level, p = 0.05). At T1, 37 patients were available. At T0, control and test groups had mean STH values of 2.3 ± 0.3mm and 2.1 ± 0.4mm. TR revealed mean STH values of 2.3 ± 0.2mm (control) and 2.6 ± 0.7mm (test), with a significant tissue thickening of 0.5 ± 0.6mm in the test group (p < 0.03). At T1, control and test groups showed MBL mean values of 1.1 ± 0.8mm and 1.0 ± 0.6mm, with a moderate but significant correlation with STH thickening (-0.34), implant position (0.43), history of periodontitis (0.39), and smoking status (0.27). The use of an aCS protocol resulted in soft tissue thickening but did not reach a threshold to reliably reduce MBL compared to the control group within the study's limitations. Peri-implant STH is crucial for maintaining peri-implant marginal bone stability. Marginal bone stability represents a crucial factor in prevention of peri-implantitis development. German register of clinical trial registration number DRKS00033290.